Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 126 Results

Title
Intervention Indication Therapeutic Area Year Actions
Dasatinib (Sprycel) tablets for children with type II variation, philadelphia positive acute lymphoblastic leukaemia Dasatinib (Sprycel; BMS 354825; dasatinib monohydrate) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
Denosumab for the prevention of skeletal related events in patients with multiple myeloma – first line Denosumab (AMG 162; Prolia; Xgeva) Prevention of skeletal related events in multiple myeloma Haematological Cancer and Lymphomas , Musculoskeletal System 2017 View  |  Download
Duvelisib for Relapsed or Refractory Chronic Lymphocytic Leukaemia Duvelisib (ABBV-954; INK-1197; IPI-145; Copiktra) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2021 View  |  Download
Duvelisib for treating relapsed and/or refractory peripheral T-cell lymphoma Duvelisib (ABBV-954; INK-1197; IPI-145; Copiktra) Peripheral T-cell lymphoma (PTCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Elotuzumab in combination with pomalidomide and low-dose dexamethasone for relapsed and refractory multiple myeloma – third line Dexamethasone (dexamethasone sodium metasulfobenzoate) , Elotuzumab (Empliciti; BMS-901608; HuLuc63) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Elranatamab for treating relapsed /refractory multiple myeloma Elranatamab (PF-06863135) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2021 View  |  Download
Enasidenib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an Isocitrate Dehydrogenase 2 (IDH2) Mutation Enasidenib (Idhifa; AG-221; CC-90007) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Entrectinib for the Treatment of NTRK-fusion Positive Solid Tumours in Adult and Paediatric Patients Entrectinib (RXDX-101) Solid tumours Haematological Cancer and Lymphomas , Oncology 2018 View  |  Download
Epcoritamab for diffuse large B-cell lymphoma after two previous treatments Epcoritamab (GEN-3013) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2021 View  |  Download
Erdafitinib for treating advanced solid tumours with an FGFR mutation in people aged 6 years and older Erdafitinib (JNJ-42756493; BALVERSA) Solid tumours Haematological Cancer and Lymphomas , Oncology 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications